Morgan Stanley
CYTO

Morgan Stanley’s Altamira Therapeutics Ltd CYTO Stock Holding History

Morgan Stanley’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-933
Closed -$1.04K – 8165
2024
Q2 		$1.04K Buy
+933
New +$1.43K ﹤0.01% 7149
2023
Q4 		– Sell
-25
Closed -$122 – 8022
2023
Q3 		$122 Hold
25
– – ﹤0.01% 7430
2023
Q2 		$321 Sell
25
-26
-51% -$513 ﹤0.01% 7417
2023
Q1 		$1.31K Sell
51
-74
-59% -$4.25K ﹤0.01% 7314
2022
Q4 		$12.1K Sell
125
-22
-15% -$2.56K ﹤0.01% 6874
2022
Q3 		$17K Buy
147
+81
+123% +$13.4K ﹤0.01% 6876
2022
Q2 		$13K Buy
66
+45
+214% +$14.5K ﹤0.01% 7147
2022
Q1 		$9K Buy
21
+1
+5% +$483 ﹤0.01% 7447
2021
Q4 		$15K Sell
20
-19
-49% -$12.7K ﹤0.01% 7331
2021
Q3 		$31K Buy
39
+6
+18% +$6.76K ﹤0.01% 6917
2021
Q2 		$46K Hold
33
– – ﹤0.01% 6706
2021
Q1 		$45K Buy
+33
New +$44.2K ﹤0.01% 6395
2020
Q4 		– Hold
0
– – – 7155
2020
Q3 		– Sell
-24
Closed -$9.03K – 6869
2020
Q2 		$9K Sell
24
-13
-35% -$4.88K ﹤0.01% 6195
2020
Q1 		$12K Sell
37
-28
-43% -$13.8K ﹤0.01% 5979
2019
Q4 		$42K Buy
65
+34
+110% +$23K ﹤0.01% 5907
2019
Q3 		$34K Sell
31
-32
-51% -$35.4K ﹤0.01% 5860
2019
Q2 		$70K Buy
63
+57
+950% +$99K ﹤0.01% 5480
2019
Q1 		$17K Buy
+6
New +$19.3K ﹤0.01% 6062
2018
Q4 		– Sell
-32
Closed -$164K – 6786
2018
Q3 		$92K Sell
32
-34
-52% -$89.5K ﹤0.01% 5718
2018
Q2 		$411K Buy
66
+47
+247% +$496K ﹤0.01% 5226
2018
Q1 		$243K Buy
19
+7
+58% +$187K ﹤0.01% 5391
2017
Q4 		$584K Buy
12
+5
+71% +$272K ﹤0.01% 4882
2017
Q3 		$447K Buy
7
+2
+40% +$122K ﹤0.01% 4952
2017
Q2 		$265K Buy
5
+3
+150% +$169K ﹤0.01% 5180
2017
Q1 		$138K Buy
+2
New +$160K ﹤0.01% 5487
2016
Q4 		– Hold
0
– – – 6586
2016
Q3 		– Hold
0
– – – 6451
2016
Q2 		– Hold
0
– – – 6378
2016
Q1 		– Hold
0
– – – 6414
2015
Q4 		– Hold
0
– – – 5646
2015
Q3 		– Hold
0
– – – 5798
2015
Q2 		– Hold
0
– – – 6523
2015
Q1 		– Hold
0
– – – 6500
2014
Q4 		– Hold
0
– -$50K – 6701
2014
Q3 		– Hold
0
– – – 5739

Other funds holding CYTO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Morgan Stanley's CYTO Position: Q3 2024 in Review

Morgan Stanley sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2024, closing a stake of 933 shares — an estimated $1.04K sold.

Morgan Stanley first reported a position in CYTO in Q1 2017 and held it in 25 quarters. The position peaked at $584K in Q4 2017. 5 funds tracked by Wall St. Rank hold CYTO as of Q3 2024.

  • Morgan Stanley reported no remaining Altamira Therapeutics Ltd position as of Q3 2024 after selling out during the quarter.
  • Morgan Stanley sold 933 Altamira Therapeutics Ltd shares in Q3 2024, an estimated $1.04K.
  • Morgan Stanley first reported a position in Altamira Therapeutics Ltd in Q1 2017 and held it in 25 quarters.
  • Morgan Stanley's Altamira Therapeutics Ltd position peaked at $584K in Q4 2017.
  • 5 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.